Format

Send to

Choose Destination
Histol Histopathol. 2012 Feb;27(2):157-70. doi: 10.14670/HH-27.157.

New models towards assessing anti-cancer therapeutics.

Author information

1
Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/University of Salamanca, Salamanca, Spain.

Abstract

Cancer is the subject of intense research around the world, but many questions about how the disease works remain unanswered. How exactly does cancer start and how do tumours grow? In fact, at present there are ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. However, many of the new anticancer agents are predicted to show clinical benefit in only small subpopulations of patients. The cancer stem cell model could explain not only how some cancers work but also why patients suffer relapses, providing a good opportunity to gain insight into the reasons why agents work or, more commonly, don't work, before going into a clinical trial.

PMID:
22207550
DOI:
10.14670/HH-27.157
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Sercrisma International S.L. Icon for Digital CSIC Spanish National Research Council
Loading ...
Support Center